secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2022-03-04T23:59:59+00:00
Accession:  0001104659-22-030623
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen: FDA declines to issue EUA for COVAXIN in pediatric population (ages 2-18)
--------------------------------------------------------------------------------

- CFO Sanjay Subramanian resigns effective March 18, 2022; no disagreement with company.
- Board appoints Jessica Crespo (VP Corporate Controller) as Chief Accounting Officer and SVP Finance.
- FDA declined to issue Emergency Use Authorization for COVAXIN for ages 2-18.
- Ocugen intends to continue working with FDA to evaluate regulatory pathway for pediatric use.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465922030623/0001104659-22-030623-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465922030623/tm228454d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-030623

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer